keyword
MENU ▼
Read by QxMD icon Read
search

Children hodgkin lymphoma

keyword
https://www.readbyqxmd.com/read/29120974/plasma-7-hydroxymethotrexate-levels-versus-methotrexate-to-predict-delayed-elimination-in-children-receiving-high-dose-methotrexate
#1
Nicolas Fabresse, Bénédicte Devictor, Christel Pissier, Hervé Chambost, Bruno Lacarelle, Gérard Michel, Caroline Solas
BACKGROUND: The aim of this study was to investigate the correlation between 7-hydroxymethotrexate (7-OHMTX) and creatinine and to evaluate the predictive value of 7-OHMTX levels on delayed elimination at 24 and 48 hours. In addition, differences in methotrexate (MTX), 7-OHMTX levels, and MTX metabolism using the ratio MTX/7-OHMTX were determined according to age. METHODS: The authors included a total of 106 cycles, corresponding to 33 patients (mean age: 9.8 years, range: 2-18 years) suffering from acute lymphoblastic leukemia, non-Hodgkin lymphoma and osteosarcoma and receiving high-dose MTX (HD-MTX)...
November 8, 2017: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/29094094/pediatric-hodgkin-lymphoma-treated-at-cancer-institute-chennai-india-long-term-outcome
#2
Venkatraman Radhakrishnan, Manikandan Dhanushkodi, Trivadi S Ganesan, Prasanth Ganesan, Shirley Sundersingh, Ganesarajah Selvaluxmy, Rajaraman Swaminathan, Ranganathan Rama, Tenali Gnana Sagar
Purpose: Pediatric Hodgkin lymphoma (HL) is a highly curable malignancy. Outcomes for pediatric HL may vary between developed and developing countries for multiple reasons. This study was conducted to ascertain the outcomes of children with HL at our center and to identify risk factors for recurrent disease. Methods: We analyzed the outcomes of 172 consecutive, previously untreated patients with pediatric HL presenting at our center from 2001 to 2010. Patients were treated with either adriamycin, bleomycin, vinblastine, and dacarbazine or adriamycin, bleomycin, vinblastine, cyclophosphamide, vincristine, prednisone, and procarbazine chemotherapy initially, and radiation to bulky sites or a single site of residual disease when appropriate...
October 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/29078819/cytokines-associated-with-burkitt-s-lymphoma-in-western-kenya
#3
Isaac Ndede, Simeon K Mining, Kirtika Patel, Fredrick M Wanjala, David Chumba, Constance Tenge
OBJECTIVE: Burkitt's lymphoma (BL) is a common aggressive non-Hodgkin's lymphoma in East and Central Africa among children. Persistent infections with Epstein Barr virus or Plasmodium falciparum are associated with immune hyperstimulation. It is hypothesised that inadvertent cytokine responses to infections indirectly or directly influence B cell neoplastic transformation through c-myelocytomatosis (c-myc) gene translocation. We sought to describe cytokines in children and adolescents with BL...
October 27, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/28986643/risk-factors-and-reasons-for-treatment-abandonment-among-children-with-lymphoma-in-malawi
#4
Christopher C Stanley, Toon van der Gronde, Kate D Westmoreland, Ande Salima, Amy Amuquandoh, Salama Itimu, Agness Manda, Idah Mtete, Mercy Butia, Atupele Mpasa, Stella Wachepa, Paula Fox, Peter Wasswa, Peter Kazembe, Nader K El-Mallawany, Satish Gopal
PURPOSE: Lymphoma is the commonest pediatric cancer in sub-Saharan Africa (SSA). Frequent treatment abandonment contributes to suboptimal outcomes. We examined risk factors and reasons for treatment abandonment for this population in Malawi. METHODS: We conducted a mixed methods study among children < 18 years old with newly diagnosed lymphoma, prospectively enrolled during 2013-2016. All children received standardized diagnosis and treatment, and were followed for up to 2 years...
October 7, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28983060/results-and-conclusions-of-the-european-intergroup-euro-lb02-trial-in-children-and-adolescents-with-lymphoblastic-lymphoma
#5
Eva Landmann, Birgit Burkhardt, Martin Zimmermann, Ulrike Meyer, Wilhelm Woessmann, Wolfram Klapper, Grazyna Wrobel, Angelo Rosolen, Marta Pillon, Gabriele Escherich, Andishe Attarbaschi, Auke Beishuizen, Karin Mellgren, Robert Wynn, Richard Ratei, Adriana Plesa, Martin Schrappe, Alfred Reiter, Christophe Bergeron, Catherine Patte, Yves Bertrand
In the European Intergroup EURO-LB02 Trial, children and adolescents with lymphoblastic lymphoma underwent the Non-Hodgkin's Lymphoma-Berlin-Frankfurt-Munster protocol without prophylactic cranial radiotherapy. Primary aims were to test whether replacing prednisone with dexamethasone during induction increases EFS in the T-cell lymphoblastic lymphoma subgroup and whether therapy duration can be reduced from 24 to 18 months (factorial design, randomizations). These questions could not be answered due to premature closure of the trial...
October 5, 2017: Haematologica
https://www.readbyqxmd.com/read/28978862/recent-progress-in-the-treatment-of-pediatric-lymphoma-in-japan
#6
Tetsuo Mitsui
Both treatment and prognosis of pediatric non-Hodgkin lymphoma (NHL) have improved dramatically in the last 30 years. Currently, localized or limited-stage NHL (stage I to II) has an approximately 95%-100% 5-year event-free survival (EFS) rate. Furthermore, the prognosis for children with advanced-stage disease (stage III to IV) has doubled from approximately 40% 5-year EFS 30 years ago to more than 80%. Hodgkin lymphoma is also known to have around 80% 10-year EFS rate. These were accomplished not only by the advancement of chemotherapy drugs but also with the global development of organizational frameworks for pediatric clinical study...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28932644/romidepsin-alone-or-in-combination-with-anti-cd20-chimeric-antigen-receptor-expanded-natural-killer-cells-targeting-burkitt-lymphoma-in-vitro-and-in-immunodeficient-mice
#7
Yaya Chu, Ashlin Yahr, Brian Huang, Janet Ayello, Matthew Barth, Mitchell S Cairo
Facilitating the development of alternative targeted therapeutic strategies is urgently required to improve outcome or circumvent chemotherapy resistance in children, adolescents, and adults with recurrent/refractory de novo mature B-cell (CD20) non-Hodgkin lymphoma, including Burkitt lymphoma (BL). Romidepsin, a histone deacetylase inhibitor (HDACi), has been used to treat cutaneous T-cell lymphoma. We have demonstrated the significant anti-tumor effect of anti-CD20 chimeric antigen receptor (CAR) modified expanded peripheral blood natural killer (exPBNK) against rituximab-sensitive and -resistant BL...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28915338/neurocognitive-psychosocial-and-quality-of-life-outcomes-in-adult-survivors-of-childhood-non-hodgkin-lymphoma
#8
Matthew J Ehrhardt, Daniel A Mulrooney, Chenghong Li, Malek J Baassiri, Kari Bjornard, John T Sandlund, Tara M Brinkman, I-Chan Huang, Deo Kumar Srivastava, Kirsten K Ness, Leslie L Robison, Melissa M Hudson, Kevin R Krull
BACKGROUND: Children with non-Hodgkin lymphoma (NHL) undergo treatment with central nervous system-directed therapy, the potentially neurotoxic effects of which have not been reported in NHL survivors. METHODS: NHL survivors (n = 187) participating in the St. Jude Lifetime Cohort who were 10 or more years from their diagnosis and were 18 years old or older underwent neurocognitive, emotional distress (Brief Symptom Inventory 18), and health-related quality of life (HRQOL) assessments (36-Item Short Form Health Survey)...
September 15, 2017: Cancer
https://www.readbyqxmd.com/read/28902390/outcomes-in-adolescents-and-young-adults-with-hodgkin-lymphoma-treated-on-us-cooperative-group-protocols-an-adult-intergroup-e2496-and-children-s-oncology-group-cog-ahod0031-comparative-analysis
#9
Tara O Henderson, Susan K Parsons, Kristen E Wroblewski, Lu Chen, Fangxin Hong, Sonali M Smith, Jennifer L McNeer, Ranjana H Advani, Randy D Gascoyne, Louis S Constine, Sandra Horning, Nancy L Bartlett, Bijal Shah, Joseph M Connors, John I Leonard, Brad S Kahl, Kara M Kelly, Cindy L Schwartz, Hongli Li, Jonathan W Friedberg, Debra L Friedman, Leo I Gordon, Andrew M Evens
BACKGROUND: There is no clear consensus between pediatric and adult providers about the treatment of adolescents and young adults (AYAs) with Hodgkin lymphoma (HL). METHODS: Failure-free survival (FFS) and overall survival (OS) were compared between 114 patients ages 17 to 21 years with HL who were treated on the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Intergroup adult E2496 study and 391 similarly patients ages 17 to 21 years with HL who were treated on the pediatric Children's Oncology Group (COG) AHOD0031 study...
September 13, 2017: Cancer
https://www.readbyqxmd.com/read/28902084/children-and-adolescent-hodgkin-lymphoma-in-argentina-long-term-results-after-combined-abvd-and-restricted-radiotherapy
#10
Pedro A Zubizarreta, Elizabeth Alfaro, Myriam Guitter, Cristian Sanchez La Rosa, María L Galluzzo, Natalia Millán, Fernando Fiandrino, María S Felice
OBJECTIVE: Prospective analysis of clinical characteristics and long-term treatment results of a pediatric cohort with Hodgkin lymphoma (HL) treated in a single institution with ABVD and restricted radiotherapy (RT). PATIENTS AND METHODS: Between September 2000 and December 2015, 165 new consecutive assessable patients with HL were registered at our institution. Lymphocyte predominant nodular HL was excluded. Low risk (LR) patients were stage I and IIA (no bulky disease, <4 involved ganglionar areas and no lung hilar nodes), high risk (HR) was assigned to stage IV and any other stage with bulky mediastinum...
November 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28883270/malignant-lymphoma-in-adolescents-and-young-adults-from-the-viewpoint-of-physicians
#11
Dai Maruyama
Malignant lymphoma (ML) is one of the most common malignancies among adolescents and young adults (AYA), accounting for approximately 20% of newly diagnosed cancers in this group. Although Hodgkin lymphoma represents only approximately 4%-5% of all cancers in children younger than 15 years of age, its incidence increases to approximately 16% in AYA. In non-Hodgkin lymphoma, the common malignancies affecting AYA include diffuse large B-cell lymphoma, Burkitt lymphoma, and anaplastic large cell lymphoma. Although it is generally accepted that AYA with ML experience outcomes that are worse than those experienced by children with ML, there are several critical issues...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28883269/malignant-lymphoma-of-adolescents-and-young-adults-from-the-viewpoint-of-pediatricians
#12
Ryoji Kobayashi, Masahiro Sekimizu
Since adolescents and young adults (AYAs) with lymphoma began to be treated by pediatric hematologists and hematology physicians, few data have been collected regarding lymphoma in this generation of patients in Japan. We analyzed the number of pediatric hospitals that have treated hematological AYA patients. In half of the pediatric facilities, patients >15 years of age had been treated, and 40% of those facilities treated >1 AYA every year. A past lymphoma study by the Japanese Pediatric Leukemia/Lymphoma Study Group included some AYA patients...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28816795/voriconazole-antifungal-prophylaxis-in-children-with-malignancies-a-nationwide-study
#13
Zoi Dorothea Pana, Maria Kourti, Katerina Vikelouda, Antonia Vlahou, Nikolaos Katzilakis, Maria Papageorgiou, Dimitrios Doganis, Loizos Petrikkos, Anna Paisiou, Dimitrios Koliouskas, Antonios Kattamis, Eftichia Stiakaki, Maria Chatzistilianou, Helen Vasilatou-Kosmidis, Sophia Polychronopoulou, Stelios Grafakos, Emmanuel Roilides
BACKGROUND: Antifungal prophylaxis (AFP) is recommended in at-risk hematology-oncology patients. We evaluated the safety of AFP with voriconazole (VRC) in pediatric hematology/oncology patients. MATERIALS AND METHODS: A retrospective study of VRC AFP in children with malignancies hospitalized in all 7 Greek pediatric hematology/oncology centers during 2008 to 2012 was conducted. Patients' demographics, outcome, and adverse event (AE) data were recorded. RESULTS: Four hundred twenty-nine VRC AFP courses in 249 patients (median age 6 y, 55% boys) were studied...
August 14, 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28802171/parental-occupational-exposure-to-benzene-and-the-risk-of-childhood-cancer-a-census-based-cohort-study
#14
Ben Daniel Spycher, Judith Eva Lupatsch, Anke Huss, Johannes Rischewski, Christina Schindera, Adrian Spoerri, Roel Vermeulen, Claudia Elisabeth Kuehni
BACKGROUND: Previous studies on occupational exposures in parents and cancer risks in their children support a link between solvents and paints with childhood leukaemia. Few studies have focused specifically on benzene. OBJECTIVES: To examine whether parental occupational exposure to benzene is associated with an increased cancer risk in a census-based cohort of children. METHODS: From a census-based cohort study in Switzerland, we included children aged <16years at national censuses (1990, 2000)...
August 9, 2017: Environment International
https://www.readbyqxmd.com/read/28802087/variant-histology-igd-and-cd30-expression-in-low-risk-pediatric-nodular-lymphocyte-predominant-hodgkin-lymphoma-a-report-from-the-children-s-oncology-group
#15
Ramona Vesna Untanu, Jason Back, Burton Appel, Qinglin Pei, Lu Chen, Allen Buxton, David C Hodgson, Peter F Ehrlich, Louis S Constine, Cindy L Schwartz, Robert E Hutchison
BACKGROUND: Histologic prognostic factors have been described for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). This study examines histologic and immunophenotypic variants in a clinical trial for pediatric NLPHL. PROCEDURE: One hundred sixty-eight cases of localized NLPHL were examined for histologic variants, CD30 and immunoglobulin D (IgD) expression, and outcome. Histologic types were scored categorically as 0 = 0, 1 ≤ 25%, and 2 > 25% of the sample...
August 12, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28771164/crosstalk-between-microrna-and-dna-methylation-offers-potential-biomarkers-and-targeted-therapies-in-alk-positive-lymphomas
#16
REVIEW
Coralie Hoareau-Aveilla, Fabienne Meggetto
The discovery of microRNA (miRNA) has provided new and powerful tools for studying the mechanism, diagnosis and treatment of human cancers. The down-regulation of tumor suppressive miRNA by hypermethylation of CpG island (CpG is shorthand for 5'-C-phosphate-G-3', that is, cytosine and guanine separated by only one phosphate) is emerging as a common hallmark of cancer and appears to be involved in drug resistance. This review discusses the role of miRNA and DNA methylation in drug resistance mechanisms and highlights their potential as anti-cancer therapies in Anaplastic Lymphoma Kinase (ALK)-positive lymphomas...
August 3, 2017: Cancers
https://www.readbyqxmd.com/read/28760045/hodgkin-lymphoma-in-children-adolescents-and-young-adults-a-comparative-study-of-clinical-presentation-and-treatment-outcome
#17
Annika Englund, Ingrid Glimelius, Klaus Rostgaard, Karin E Smedby, Sandra Eloranta, Daniel Molin, Thomas Kuusk, Peter de Nully Brown, Peter Kamper, Henrik Hjalgrim, Gustaf Ljungman, Lisa Lyngsie Hjalgrim
BACKGROUND: Hodgkin lymphoma (HL) treatment protocols for children, adolescents and young adults traditionally differ, but the biological and clinical justification for this remains uncertain. MATERIAL AND METHODS: We compared age-dependent clinical presentation and treatment and outcome for 1072 classical HL patients 0-24 years diagnosed in Denmark (1990-2010) and Sweden (1992-2009) in pediatric (n = 315, Denmark <15 years, Sweden <18 years) or adult departments (n = 757)...
August 1, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28759103/contribution-of-solid-organ-transplant-recipients-to-the-pediatric-non-hodgkin-lymphoma-burden-in-the-united-states
#18
Elizabeth L Yanik, Meredith S Shiels, Jodi M Smith, Christina A Clarke, Charles F Lynch, Amy R Kahn, Lori Koch, Karen S Pawlish, Eric A Engels
BACKGROUND: Pediatric solid organ transplant recipients have a 100 to 200 times higher risk of non-Hodgkin lymphoma (NHL) than the general pediatric population. Consequently, transplant-related NHL may contribute considerably to the pediatric NHL burden in the United States. METHODS: A cohort study using a linkage between the US transplant registry and 16 cancer registries was conducted. Cancer incidence rates were calculated for people less than 20 years old in the transplant and general populations...
December 1, 2017: Cancer
https://www.readbyqxmd.com/read/28751566/prolonged-versus-standard-native-e-coli-asparaginase-therapy-in-childhood-acute-lymphoblastic-leukemia-and-non-hodgkin-lymphoma-final-results-of-the-eortc-clg-randomized-phase-iii-trial-58951
#19
Veerle Mondelaers, Stefan Suciu, Barbara De Moerloose, Alina Ferster, Françoise Mazingue, Geneviève Plat, Karima Yakouben, Anne Uyttebroeck, Patrick Lutz, Vitor Costa, Nicolas Sirvent, Emmanuel Plouvier, Martine Munzer, Maryline Poirée, Odile Minckes, Frédéric Millot, Dominique Plantaz, Philip Maes, Claire Hoyoux, Hélène Cavé, Pierre Rohrlich, Yves Bertrand, Yves Benoit
Asparaginase is an essential component of combination chemotherapy for childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma. The value of asparaginase was further addressed in a group of non-very high-risk patients by comparing prolonged (long-asparaginase) versus standard (short-asparaginase) native E. coli asparaginase treatment in a randomized part of the phase III 58951 trial of the European Organization for Research and Treatment of Cancer Children's Leukemia Group. The main endpoint was disease-free survival...
October 2017: Haematologica
https://www.readbyqxmd.com/read/28741053/prediction-of-outcome-in-pediatric-hodgkin-lymphoma-based-on-interpretation-of-18-fdg-pet-ct-according-to-%C3%AE-suvmax-deauville-5-point-scale-and-ihp-criteria
#20
Emine Göknur Isik, Serkan Kuyumcu, Rejin Kebudi, Yasemin Sanli, Zeynep Karakas, Fatma Betul Cakir, Seher Nilgün Unal
OBJECTIVE: Minimizing side effects by using response-adopted therapy strategies plays an important role in the management of pediatric Hodgkin lymphoma (HL); however, the criteria for the definition of adequate or inadequate response are controversial. The aim of this study is to compare different methods of interpretation of (18)F-FDG-PET/CT (PET) in the prediction of disease outcome in order to determine the optimum method in this regard. METHODS: Baseline, interim and post-treatment PET scans of 72 children were interpreted according to revised International Harmonization Project criteria (IHP) and Deauville criteria...
November 2017: Annals of Nuclear Medicine
keyword
keyword
113492
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"